Frequently asked questions.

UroLongevity is a comprehensive longevity medicine practice in New York City, led by board-certified urologist David Shusterman, MD. It focuses on measuring and acting on the biology of aging early, through a proactive, integrated, and longitudinal model of care.

No. “Anti-aging” implies reversing or defeating aging, which is not an honest promise. This is a clinical practice focused on healthspan — extending the functional, healthy years — and it is candid about what the evidence does and does not support.

The practice is at 800 Second Avenue, 9th Floor, Suite C, New York, NY 10017, in Midtown Manhattan.

Longevity medicine is fundamentally a diagnostic discipline, and urology brings a particular diagnostic depth — including the use of urine analysis as a real-time metabolic window. The UroLongevity Difference page explains this in detail.

Conventional primary and specialty care is essential, and this practice does not replace it. The difference is posture and time horizon: conventional care is largely reactive and episodic, while comprehensive longevity medicine is proactive and longitudinal, working in the long window before disease arrives.

The paradigm rests on established principles of preventive medicine. Individual interventions vary in how strong their evidence is — which is exactly why every article in The Science library carries an evidence rating, and why the practice is explicit about what is settled and what is early.

No. This medicine does not cure aging, does not eliminate mortality, and reduces but does not abolish disease risk. What it offers is the chance to influence your health trajectory and extend your functional years. The What It Offers & Requires page is candid about this.

Metabolic and weight medicine, including the GLP-1 class, is one of the practice’s service areas. Whether any medication is appropriate for you is determined individually after a metabolic baseline, within a clinical relationship. Dosing is never published as general guidance.

Careful and honest. Peptides range from well-characterized therapies to compounds whose evidence is early or whose regulatory status is unsettled. The practice explains what the evidence supports, does not provide dosing or sourcing on public pages, and determines any appropriate use within supervised clinical care. See the Peptide Therapy page.

No. Specific dosing and protocols are individualized to each patient’s clinical picture and decided in consultation. Publishing one-size dosing guidance would not be good or safe medicine.

Comprehensive longevity medicine includes services that are frequently not covered by insurance. The practice is transparent about costs so you can make an informed decision before committing. Specific questions can be raised when you contact the practice.

The best first step is to book a consultation. A consultation is a conversation about your health and goals, with no obligation to proceed.

The New Patient Information page explains what to bring and how to prepare.